Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Value of Contrast-enhanced Magnetic Resonance Imaging (MRI) in the Diagnosis of Breast Cancer

Author(s): Mateus Aquino Gonçalves*, Bruna T.L. Pereira, Camila A. Tavares, Taináh M.R. Santos, Elaine F.F. da Cunha and Teodorico C. Ramalho

Volume 22, Issue 6, 2022

Published on: 13 January, 2022

Page: [865 - 872] Pages: 8

DOI: 10.2174/1389557521666210521113155

Price: $65

Abstract

This review article aims to address the main features of breast cancer. Thus, the general aspects of this disease have been shown since the first evidence of breast cancer in the world until the numbers today. In this way, there are some ways to prevent breast cancer, such as the woman's lifestyle (healthy eating habits and physical activities) that helps to reduce the incidence of this anomaly. The first noticeable symptom of this anomaly is typically a lump that feels different from the rest of the breast tissue. More than 80% of breast cancer are discovered when the woman feels a lump being present and about 90% of the cases, the cancer is noticed by the woman herself. Currently, the most used method for the detection of cancer and other injuries is the Magnetic Resonance Imaging (MRI) technique. This technique has been shown to be very effective, however, for a better visualization of the images, Contrast Agents (CAs) are used, which are paramagnetic compounds capable of increasing the relaxation of the hydrogen atoms of the water molecules present in the body tissues. The most used CAs are Gd3+ complexes, although they are very efficient, they are toxic to the organism. Thus, new contrast agents have been studied to replace Gd3+ complexes; we can mention iron oxides as a promising substitute.

Keywords: Cancer, diagnosis, MRI, Contrast Agents, breast, relaxation time.

« Previous Next »
Graphical Abstract

[1]
Fernander, A.G.; Mafra, D. Zinco e câncer: Uma revisão. Revista Saúde. Com, 2005, 1, 144-156.
[2]
Almeida, V.L.; Leitão, A.; Reina, L.C.B.; Montanari, C.A.; Donnici, C.L.; Lopes, M.T. Câncer e agentes antineoplásicos ciclo-celular específicos e ciclo-celular não específicos que interagem com o DNA: uma introdução. Quim. Nova, 2005, 28, 118-129.
[http://dx.doi.org/10.1590/S0100-40422005000100021]
[3]
Chala, L.F.; Barros, N. Editorial avaliação das mamas com métodos de imagem. Radiol. Bras., 2007, 40, 1-3.
[http://dx.doi.org/10.1590/S0100-39842007000100001]
[4]
Araujo, D. N.; Dantas, D.S.; Nascimento, R. S. T. R. Efeitos do exercício físico em mulheres com câncer de mama submetidas à radioterapia: Uma revisão sistemática. ACM, 2012, 41, 78-82.
[5]
Sartori, A.C.N.; Basso, C.S. Câncer de mama: Uma breve revisão da literatura. Perprspectiva, 2019, 43, 7-13.
[6]
Siu, A.L.U.S. Preventive services task force. Screening for breast cancer: U.S. Preventive services task force recommendation statement. Ann. Intern. Med., 2016, 164(4), 279-296.
[http://dx.doi.org/10.7326/M15-2886] [PMID: 26757170]
[7]
Mustafa, M.; Nornazirah, A.; Salih, F.A.; Illzam, E.L.; Suleiman, M.; Sharifa, A.M. Breast cancer: Detection markers, prognosis, and prevention. IJSRDMS, 2016, 15, 73-80.
[http://dx.doi.org/10.9790/0853-1508117380]
[8]
Marques, M.S.; Haddad, C.A.S. A importância do exercício físico no pós-operatório imediato de câncer de mama. Revista UNILUS Ensino e Pesquisa, 2014, 11, 54-56.
[9]
Lima, A.P.; Barbosa, L.A.; Rocha, A.C. Câncer de mama em homem jovem com ginecomastia: relato de caso. Mastology, 2015, 25, 103-107.
[http://dx.doi.org/10.5327/Z201500030008RBM]
[10]
Leme, L.H.S. SOUZA GA. Câncer de mama em homens: aspectos epidemiológicos, clínicos e terpêuticos. Rev. Cienc. Méd., 2006, 15, 391-398.
[11]
Deepinder, F.; Braunstein, G.D. Drug-induced gynecomastia: An evidence-based review. Expert Opin. Drug Saf., 2012, 11(5), 779-795.
[http://dx.doi.org/10.1517/14740338.2012.712109] [PMID: 22862307]
[12]
Johson, K.C.; Millar, J.; Turcotte, F. Active smoking and second smoke increase breast cancer risk: The report of canadian expert panel on tobacco smoke and breast cancer risk. Tob. Control, 2011, 20, 1-6.
[13]
Nelson, H.D.; Smith, M.E.; Griffin, J.C.; Fu, R. Use of medications to reduce risk for primary breast cancer: A systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med., 2013, 158(8), 604-614.
[http://dx.doi.org/10.7326/0003-4819-158-8-201304160-00005] [PMID: 23588749]
[14]
Lifestyle-related Breast Cancer Risk Factors. Available at: www.cancer.orgAccessed Sep 22, 2020
[15]
World Health Organization Breast cancer: Prevention and control; World Health Organization; Geneva: Swtzerland, 2009.
[16]
Shield, K.D.; Soerjomataram, I.; Rehm, J. Alcohol use and breast cancer: A critical review. Alcohol. Clin. Exp. Res., 2016, 40(6), 1166-1181.
[http://dx.doi.org/10.1111/acer.13071] [PMID: 27130687]
[17]
BRAY. F.; MCCARRON, P.; PARKIN, D.M. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res., 2014, 6, 229-239.
[18]
Blackburn, G.L.; Wang, K.A. Dietary fat reduction and breast cancer outcome: Results from the Women’s Intervention Nutrition Study (WINS). Am. J. Clin. Nutr., 2007, 86(3), s878-s881.
[http://dx.doi.org/10.1093/ajcn/86.3.878S] [PMID: 18265482]
[19]
Asaria, P.; Chisholm, D.; Mathers, C.; Ezzati, M.; Beaglehole, R. Chronic disease prevention: Health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet, 2007, 370(9604), 2044-2053.
[http://dx.doi.org/10.1016/S0140-6736(07)61698-5] [PMID: 18063027]
[20]
Merk manual of diagnosis and therapy. Breast Disorders: Overview of Breast Disorders, Available at:. https://www.merckmanuals.com/home/women-s-health-issues/breast-disorders/breast-cancerAccessedSep 22,;2020
[21]
Ferlay, J.; Bray, F.; Pisani, P.; Parkin, D.M. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide IARC Cancer Base. Int. J. Cancer, 2001, 94, 153-156.
[22]
Abreu, E.; Koifman, S. Fatores prognóstico no câncer de mama feminina. Rev. Bras. Cancerol., 2002, 48, 113-131.
[23]
Mauri, D.; Pavlidis, N.; Ioannidis, J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J. Natl. Cancer Inst., 2005, 97(3), 188-194.
[http://dx.doi.org/10.1093/jnci/dji021] [PMID: 15687361]
[24]
National Cancer Institute. Radiation Therapy for Cancer, Available at: https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy Accessed Sep 22, 2020
[25]
Giordano, S.H.; Hortobagyi, G.N.; Kau, S.W.; Theriault, R.L.; Bondy, M.L. Breast cancer treatment guidelines in older women. J. Clin. Oncol., 2005, 23(4), 783-791.
[http://dx.doi.org/10.1200/JCO.2005.04.175] [PMID: 15681522]
[26]
Bradley, C.J.; Given, C.W.; Roberts, C. Race, socioeconomic status, and breast cancer treatment and survival. J. Natl. Cancer Inst., 2002, 94(7), 490-496.
[http://dx.doi.org/10.1093/jnci/94.7.490] [PMID: 11929949]
[27]
Bickell, N.A.; Wang, J.J.; Oluwole, S.; Schrag, D.; Godfrey, H.; Hiotis, K.; Mendez, J.; Guth, A.A. Missed opportunities: Racial disparities in adjuvant breast cancer treatment. J. Clin. Oncol., 2006, 24(9), 1357-1362.
[http://dx.doi.org/10.1200/JCO.2005.04.5799] [PMID: 16549830]
[28]
Atlas, S.W.; Howard, R.S., II; Maldjian, J.; Alsop, D.; Detre, J.A.; Listerud, J.; D’Esposito, M.; Judy, K.D.; Zager, E.; Stecker, M. Functional magnetic resonance imaging of regional brain activity in patients with intracerebral gliomas: findings and implications for clinical management. Neurosurgery, 1996, 38(2), 329-338.
[http://dx.doi.org/10.1097/00006123-199602000-00019] [PMID: 8869061]
[29]
Wehrli, F.W. From NMR diffraction and zeugmatography. Prog. Nucl. Mag. Res. SP, 1995, 1995(28), 87-135.
[http://dx.doi.org/10.1016/0079-6565(95)01021-1]
[30]
Dolui, s.; Vidorreta, M.; Nasrallah, I.; Wolk, D.; Detre, J. Periventricular cerebral blood flow as a biomarker for cerebral small vessel disease. Neurology, 2019, 92, 1-15.
[31]
Covolan, R.; Araújo, D.B.; Santos, A.C.; Cendes, F. Ressonância magnética funcional: As funções do cerébro reveladas pos spin nucleares. Cienc. Cult., 2004, 56, 40-42.
[32]
Mazzola, A.A. Ressonância magnética : Princípios de formação da imagem e aplicações em imagem funcional Magnetic resonance : Principles of image formation and applications in funcional imaging. Rev. Bras. Ensino Fis., 2009, 3, 117-129.
[33]
Park, A.Y.; Seo, B.K. Real-Time MRI navigated ultrasound for preoperative tumor evaluation in breast cancer patients: Technique and clinical implementation. Korean J. Radiol., 2016, 17(5), 695-705.
[http://dx.doi.org/10.3348/kjr.2016.17.5.695] [PMID: 27587958]
[34]
Gonçalves, M.A.; Peixoto, F.C.; Cunha, E.F.F.; Ramalho, T.C. Dynamics, NMR parameters and hyperfine coupling constants of the Fe3O4(100)–water interface: Implications for MRI probes. Chem. Phys. Lett., 2014, 609, 88-92.
[http://dx.doi.org/10.1016/j.cplett.2014.06.030]
[35]
Lepage, M.; Gore, J.C. Contrast mechanisms in magnetic resonance imaging. J. Phys., 2004, 3, 78-86.
[36]
Yazyev, O.V.; Helm, L.; Malkin, V.G.; Malkina, O.L. Quantum chemical investigation of hyperfine coupling constants on first coordination sphere water molecule of gadolinium(III) aqua complexes. J. Phys. Chem. A, 2005, 109(48), 10997-11005.
[http://dx.doi.org/10.1021/jp053825+] [PMID: 16331943]
[37]
Gonçalves, M.A.; da Cunha, E.F.F.; Peixoto, F.C.; Ramalho, T.C. Probing thermal and solvent effects on hyperfine interactions and spin relaxation rate of d-FeOOH(100) and [MnH3buea(OH)]2-: Toward new MRI probes. Comput. Theor. Chem., 2015, 1069, 96-104.
[http://dx.doi.org/10.1016/j.comptc.2015.07.006]
[38]
Cacheris, W.P.; Quay, S.C.; Rocklage, S.M. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn. Reson. Imaging, 1990, 8(4), 467-481.
[http://dx.doi.org/10.1016/0730-725X(90)90055-7] [PMID: 2118207]
[39]
Gonçalves, M.A.; Ramalho, T.C. Agentes de Contraste para Ressonância Magnética de Imagem: Uma revisão. Rev. Virtual Quim., 2017, 9, 1511-1524.
[http://dx.doi.org/10.21577/1984-6835.20170087]
[40]
Gonçalves, M.A.; Santos, L.S.; Peixoto, F.C.; da Cunha, E.F.F.; Silva, T.C.; Ramalho, T.C. Comparing structure and dynamics of solvation of different iron oxide phases for enhanced magnetic resonance imaging. Chem. Select, 2017, 2, 10136-10142.
[http://dx.doi.org/10.1002/slct.201701705]
[41]
Oviedo, C.; Rodrigues, J. EDTA: The chelating agent under environmental scrutiny. Quim. Nova, 2003, 26, 901-905.
[http://dx.doi.org/10.1590/S0100-40422003000600020]
[42]
Fang, X.; Cao, J.; Shen, A. Advances in anti-breast cancer drugs and the application of nano-drug delivery systems in breast cancer therapy. J. Drug Deliv. Sci. Technol., 2020, 57, 101662-101678.
[http://dx.doi.org/10.1016/j.jddst.2020.101662]
[43]
Mendes, R.F.; Figueira, F.; Leite, J.P.; Gales, L.; Almeida Paz, F.A. Metal-organic frameworks: a future toolbox for biomedicine? Chem. Soc. Rev., 2020, 49(24), 9121-9153.
[http://dx.doi.org/10.1039/D0CS00883D] [PMID: 33136108]
[44]
Luo, Z.; Fan, S.; Gu, C.; Liu, W.; Chen, J.; Li, B.; Liu, J. Metal-Organic framework (MOF)-based nanomaterials for biomedical applications. Curr. Med. Chem., 2019, 26(18), 3341-3369.
[http://dx.doi.org/10.2174/0929867325666180214123500] [PMID: 29446726]
[45]
Shen, X.; Pan, Y.; Sun, Z.; Liu, D.; Xu, H.; Yu, Q.; Trivedi, M.; Kumar, A.; Chen, J.; Liu, J. Design of Metal-Organic frameworks for pH-Responsive drug delivery application. Mini Rev. Med. Chem., 2019, 19(20), 1644-1665.
[http://dx.doi.org/10.2174/1389557519666190722164247] [PMID: 31880236]
[46]
Cabioglu, N.; Hunt, K.K.; Buchholz, T.A.; Mirza, N.; Singletary, S.E.; Kuerer, H.M.; Babiera, G.V.; Ames, F.C.; Sahin, A.A.; Meric-Bernstam, F. Improving local control with breast-conserving therapy: A 27-year single-institution experience. Cancer, 2005, 104(1), 20-29.
[http://dx.doi.org/10.1002/cncr.21121] [PMID: 15912514]
[47]
Bradley, C.J.; Given, C.W.; Roberts, C. Disparities in cancer diagnosis and survival. Cancer, 2001, 91(1), 178-188.
[http://dx.doi.org/10.1002/1097-0142(20010101)91:1<178:AID-CNCR23>3.0.CO;2-S] [PMID: 11148575]
[48]
Mandelblatt, J.S.; Kerner, J.F.; Hadley, J.; Hwang, Y.T.; Eggert, L.; Johnson, L.E.; Gold, K. OPTIONS (Outcomes and Preferences for Treatment in Older Women Nationwide Study). Variations in breast carcinoma treatment in older medicare beneficiaries: Is it black or white. Cancer, 2002, 95(7), 1401-1414.
[http://dx.doi.org/10.1002/cncr.10825] [PMID: 12237908]
[49]
Xu, F.; Cheng, C.; Chen, D.X.; Gu, H. Magnetite nanocrystal clusters with ultra-high sensitivity in magnetic resonance imaging. ChemPhysChem, 2012, 13(1), 336-341.
[http://dx.doi.org/10.1002/cphc.201100548] [PMID: 22095763]
[50]
Khosroshahi, M.E.; Rezvani, H.A.; Keshvari, H.; Bonakdar, S.; Tajabadi, M. Evaluation of cell viability and T2 relaxivity of fluorescein conjugated SPION-PAMAM third generation nanodendrimers for bioimaging. Mater. Sci. Eng. C, 2016, 62, 544-552.
[http://dx.doi.org/10.1016/j.msec.2016.01.082] [PMID: 26952457]
[51]
Tan, G.; Zhong, Y.; Yang, L.; Jiang, L.; Liu, J.; Ren, F. A multifunctional MOF-based nanohybrid as injectable implant platform for drug synergistic oral cancer therapy. Chem. Eng. Sci., 2020, 390, 1-13.
[52]
Zhong, Y.; Li, X.; Chen, J.; Wang, X.; Wei, L.; Fang, L.; Kumar, A.; Zhuang, S.; Liu, J. Recent advances in MOF-based nanoplatforms generating reactive species for chemodynamic therapy. Dalton Trans., 2020, 49(32), 11045-11058.
[http://dx.doi.org/10.1039/D0DT01882A] [PMID: 32756684]
[53]
Improving MRI contrast : Contrast agentes Available at: https://www.imaios.com/es/e-Cursos/e-MRI/Improving-MRI-contrast-Contrast-agents/gadolinium-mriAccessedJan 20,;2021
[54]
Mazzola, A.A.; Stieven, K.I.; Neto, G.H.; Cardoso, G. de M. Segurança em Imagem por Ressonância Magnética. Rev. Bras. Ensino Fis., 2019, 13, 76-91.
[55]
Utilização racional dos exames de imagem em medicina. Available at: https://drpixel.fcm.unicamp.br/conteudo/utilizacao-racional-dos-exames-de-imagem-em-medicina#:~:text=Figura%202%20%2D%20Resson%C3%A2ncia%20magn%C3%A9tica%20de,axilas%20e%20da%20parede%20tor%C3%A1cicaAccessedJan 20,;2021
[56]
Chung, S.M. Safety issues in magnetic resonance imaging. J. Neuroophthalmol., 2002, 22(1), 35-39.
[http://dx.doi.org/10.1097/00041327-200203000-00009] [PMID: 11937904]
[57]
Kanal, E.; Barkovich, A.J.; Bell, C.; Borgstede, J.P.; Bradley, W.G., Jr; Froelich, J.W.; Gimbel, J.R.; Gosbee, J.W.; Kuhni-Kaminski, E.; Larson, P.A.; Lester, J.W., Jr; Nyenhuis, J.; Schaefer, D.J.; Sebek, E.A.; Weinreb, J.; Wilkoff, B.L.; Woods, T.O.; Lucey, L. Hernandez, D Expert Panel on MR Safety. ACR guidance document on MR safe practices: 2013. J. Magn. Reson. Imaging, 2013, 37, 501-530.

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy